Marc A. Pfeffer

143.8k total citations · 54 hit papers
596 papers, 95.5k citations indexed

About

Marc A. Pfeffer is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Endocrinology, Diabetes and Metabolism. According to data from OpenAlex, Marc A. Pfeffer has authored 596 papers receiving a total of 95.5k indexed citations (citations by other indexed papers that have themselves been cited), including 464 papers in Cardiology and Cardiovascular Medicine, 107 papers in Surgery and 84 papers in Endocrinology, Diabetes and Metabolism. Recurrent topics in Marc A. Pfeffer's work include Heart Failure Treatment and Management (249 papers), Cardiovascular Function and Risk Factors (234 papers) and Blood Pressure and Hypertension Studies (79 papers). Marc A. Pfeffer is often cited by papers focused on Heart Failure Treatment and Management (249 papers), Cardiovascular Function and Risk Factors (234 papers) and Blood Pressure and Hypertension Studies (79 papers). Marc A. Pfeffer collaborates with scholars based in United States, Canada and United Kingdom. Marc A. Pfeffer's co-authors include John J.V. McMurray, Eugene Braunwald, Scott D. Solomon, Eugene Braunwald, Jean L. Rouleau, Frank M. Sacks, Salim Yusuf, Karl Swedberg, Lemuel A. Moyé and Christopher B. Granger and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Marc A. Pfeffer

584 papers receiving 91.3k citations

Hit Papers

The Effect of Pravastatin on Coronary Events after Myoc... 1979 2026 1994 2010 1996 1992 2004 1990 2009 1000 2.0k 3.0k 4.0k 5.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol Levels
    1996 5.7k citations Marc A. Pfeffer, Jean L. Rouleau et al. New England Journal of Medicine profile →
  2. Effect of Captopril on Mortality and Morbidity in Patients with Left Ventricular Dysfunction after Myocardial Infarction
    1992 4.4k citations Marc A. Pfeffer, Eugene Braunwald et al. New England Journal of Medicine profile →
  3. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
    2004 3.4k citations Christopher P. Cannon, Eugene Braunwald et al. New England Journal of Medicine profile →
  4. Ventricular remodeling after myocardial infarction. Experimental observations and clinical implications.
    1990 2.3k citations Marc A. Pfeffer et al. Circulation profile →
  5. Cardiac-Resynchronization Therapy for the Prevention of Heart-Failure Events
    2009 2.0k citations Marc A. Pfeffer, Scott D. Solomon et al. New England Journal of Medicine profile →
  6. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial
    2003 2.0k citations Salim Yusuf, Marc A. Pfeffer et al. profile →
  7. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial
    2003 1.8k citations John J.V. McMurray, Jan Östergren et al. profile →
  8. Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
    2015 1.7k citations Marc A. Pfeffer, Rafael Díaz et al. New England Journal of Medicine profile →
  9. C-Reactive Protein Levels and Outcomes after Statin Therapy
    2005 1.7k citations Paul M. Ridker, Christopher P. Cannon et al. New England Journal of Medicine profile →
  10. Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both
    2003 1.7k citations Marc A. Pfeffer, John J.V. McMurray et al. New England Journal of Medicine profile →
  11. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
    2006 1.6k citations Marc A. Pfeffer et al. Circulation profile →
  12. Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
    2005 1.6k citations Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine profile →
  13. Relation between Renal Dysfunction and Cardiovascular Outcomes after Myocardial Infarction
    2004 1.5k citations John J.V. McMurray, Eric J. Velazquez et al. New England Journal of Medicine profile →
  14. Renin–Angiotensin–Aldosterone System Inhibitors in Patients with Covid-19
    2020 1.4k citations Muthiah Vaduganathan, Orly Vardeny et al. New England Journal of Medicine profile →
  15. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme
    2003 1.3k citations Marc A. Pfeffer, Karl Swedberg et al. profile →
  16. Long-Term Effects of Pravastatin on Plasma Concentration of C-reactive Protein
    1999 1.2k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  17. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial
    2003 1.1k citations Christopher B. Granger, John J.V. McMurray et al. profile →
  18. Inflammation, Pravastatin, and the Risk of Coronary Events After Myocardial Infarction in Patients With Average Cholesterol Levels
    1998 1.1k citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  19. Myocardial infarct size and ventricular function in rats.
    1979 1.1k citations Marc A. Pfeffer, Eugene Braunwald et al. profile →
  20. Long-term ACE-inhibitor therapy in patients with heart failure or left-ventricular dysfunction: a systematic overview of data from individual patients
    2000 1.1k citations Salim Yusuf, Lars Køber et al. profile →
  21. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes
    2004 971 citations James A. de Lemos, Eldrin F. Lewis et al. JAMA profile →
  22. Kidney Disease as a Risk Factor for Development of Cardiovascular Disease
    2003 874 citations Andrew S. Levey, Marc A. Pfeffer et al. profile →
  23. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes
    2012 863 citations John J.V. McMurray, Scott D. Solomon et al. New England Journal of Medicine profile →
  24. Effect of Captopril on Progressive Ventricular Dilatation after Anterior Myocardial Infarction
    1988 824 citations Marc A. Pfeffer, Gervasio A. Lamas et al. New England Journal of Medicine profile →
  25. A Prospective Evaluation of an Angiotensin-Converting–Enzyme Gene Polymorphism and the Risk of Ischemic Heart Disease
    1995 785 citations Marc A. Pfeffer et al. New England Journal of Medicine profile →
  26. Elevation of Tumor Necrosis Factor-α and Increased Risk of Recurrent Coronary Events After Myocardial Infarction
    2000 777 citations Paul M. Ridker, Nader Rifai et al. Circulation profile →
  27. Predictors of mortality and morbidity in patients with chronic heart failure
    2005 757 citations Stuart Pocock, Duolao Wang et al. European Heart Journal profile →
  28. Red Cell Distribution Width as a Novel Prognostic Marker in Heart Failure
    2007 752 citations Stuart Pocock, John J.V. McMurray et al. Journal of the American College of Cardiology profile →
  29. Renal Function as a Predictor of Outcome in a Broad Spectrum of Patients With Heart Failure
    2006 733 citations Marc A. Pfeffer, Karl Swedberg et al. Circulation profile →
  30. Sex Differences in the Management of Coronary Artery Disease
    1991 731 citations Milton Packer, Marc A. Pfeffer et al. New England Journal of Medicine profile →
  31. Cardiovascular Events and Their Reduction With Pravastatin in Diabetic and Glucose-Intolerant Myocardial Infarction Survivors With Average Cholesterol Levels
    1998 721 citations Marc A. Pfeffer, Eugene Braunwald et al. Circulation profile →
  32. Relation Between Serum Phosphate Level and Cardiovascular Event Rate in People With Coronary Disease
    2005 690 citations Marc A. Pfeffer et al. Circulation profile →
  33. A Sensitive Cardiac Troponin T Assay in Stable Coronary Artery Disease
    2009 667 citations Torbjørn Omland, James A. de Lemos et al. New England Journal of Medicine profile →
  34. Relation Between Red Blood Cell Distribution Width and Cardiovascular Event Rate in People With Coronary Disease
    2008 653 citations Marc A. Pfeffer et al. Circulation profile →
  35. Controversies in ventricular remodelling
    2006 639 citations Marc A. Pfeffer et al. profile →
  36. Quantitative two-dimensional echocardiographic measurements are major predictors of adverse cardiovascular events after acute myocardial infarction. The protective effects of captopril.
    1994 638 citations Marc A. Pfeffer, Gervasio A. Lamas et al. Circulation profile →
  37. Influence of chronic captopril therapy on the infarcted left ventricle of the rat.
    1985 636 citations Marc A. Pfeffer, Eugene Braunwald et al. profile →
  38. Ventricular Remodeling after Myocardial Infarction
    1993 629 citations Gervasio A. Lamas, Marc A. Pfeffer et al. profile →
  39. Heart failure
    2005 627 citations John J.V. McMurray, Marc A. Pfeffer profile →
  40. Influence of Ejection Fraction on Cardiovascular Outcomes in a Broad Spectrum of Heart Failure Patients
    2005 609 citations Scott D. Solomon, Hicham Skali et al. Circulation profile →
  41. Survival after an experimental myocardial infarction: beneficial effects of long-term therapy with captopril.
    1985 585 citations Marc A. Pfeffer et al. Circulation profile →
  42. The Heart in Hypertension
    1992 584 citations Marc A. Pfeffer et al. New England Journal of Medicine profile →
  43. Left ventricular remodeling after myocardial infarction: a corollary to infarct expansion.
    1986 564 citations Marc A. Pfeffer et al. Circulation profile →
  44. Heart Failure With Preserved Ejection Fraction In Perspective
    2019 540 citations Marc A. Pfeffer, Amil M. Shah et al. profile →
  45. AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update
    2001 536 citations Marc A. Pfeffer et al. Journal of the American College of Cardiology profile →
  46. Sudden Death in Patients with Myocardial Infarction and Left Ventricular Dysfunction, Heart Failure, or Both
    2005 525 citations Scott D. Solomon, John J.V. McMurray et al. New England Journal of Medicine profile →
  47. AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
    2006 517 citations Marc A. Pfeffer et al. Journal of the American College of Cardiology profile →
  48. AHA/ACC Guidelines for Preventing Heart Attack and Death in Patients With Atherosclerotic Cardiovascular Disease: 2001 Update
    2001 504 citations Marc A. Pfeffer et al. Circulation profile →
  49. Impact of diabetes on outcomes in patients with low and preserved ejection fraction heart failure: An analysis of the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) programme
    2008 503 citations Michael R. MacDonald, Mark C. Petrie et al. European Heart Journal profile →
  50. Clinical Significance of Mitral Regurgitation After Acute Myocardial Infarction
    1997 486 citations Gervasio A. Lamas, Marc A. Pfeffer et al. Circulation profile →
  51. Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure
    2007 457 citations Scott D. Solomon, Joanna Dobson et al. Circulation profile →
  52. Influence of ejection fraction on outcomes and efficacy of spironolactone in patients with heart failure with preserved ejection fraction
    2015 335 citations Scott D. Solomon, Brian Claggett et al. European Heart Journal profile →
  53. Prognostic Importance of Impaired Systolic Function in Heart Failure With Preserved Ejection Fraction and the Impact of Spironolactone
    2015 329 citations Amil M. Shah, Brian Claggett et al. Circulation profile →
  54. Heart Failure with Mid-Range Ejection Fraction in CHARM: Characteristics, Outcomes and Effect of Candesartan Across the Entire Ejection Fraction Spectrum
    2018 276 citations Brian Claggett, Carolyn S.P. Lam et al. European Journal of Heart Failure profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Marc A. Pfeffer United States 139 63.0k 26.3k 17.6k 9.3k 8.9k 596 95.5k
John J.V. McMurray United Kingdom 161 87.0k 1.4× 22.7k 0.9× 30.4k 1.7× 7.1k 0.8× 16.5k 1.9× 1.5k 131.6k
Daniel Levy United States 171 90.7k 1.4× 25.2k 1.0× 19.4k 1.1× 13.8k 1.5× 11.2k 1.3× 816 143.1k
Gregg C. Fonarow United States 157 79.0k 1.3× 17.6k 0.7× 10.1k 0.6× 6.7k 0.7× 14.1k 1.6× 1.8k 113.5k
Deepak L. Bhatt United States 142 57.5k 0.9× 40.1k 1.5× 23.5k 1.3× 7.9k 0.9× 14.4k 1.6× 2.0k 108.1k
Christopher P. Cannon United States 125 38.0k 0.6× 27.9k 1.1× 14.2k 0.8× 10.8k 1.2× 5.3k 0.6× 879 67.5k
Scott D. Solomon United States 140 64.9k 1.0× 13.5k 0.5× 13.2k 0.8× 9.9k 1.1× 14.1k 1.6× 1.2k 93.2k
Peter W.F. Wilson United States 156 35.2k 0.6× 31.0k 1.2× 29.9k 1.7× 6.9k 0.7× 8.1k 0.9× 646 110.5k
Martin G. Larson United States 142 53.4k 0.8× 12.7k 0.5× 9.6k 0.5× 6.6k 0.7× 8.0k 0.9× 587 89.4k
William B. Kannel United States 158 71.4k 1.1× 22.9k 0.9× 25.8k 1.5× 10.7k 1.2× 10.3k 1.2× 477 128.7k
Eugene Braunwald United States 127 50.8k 0.8× 30.6k 1.2× 12.4k 0.7× 12.1k 1.3× 4.4k 0.5× 703 77.3k

Countries citing papers authored by Marc A. Pfeffer

Since Specialization
Citations

This map shows the geographic impact of Marc A. Pfeffer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marc A. Pfeffer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marc A. Pfeffer more than expected).

Fields of papers citing papers by Marc A. Pfeffer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marc A. Pfeffer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marc A. Pfeffer. The network helps show where Marc A. Pfeffer may publish in the future.

Co-authorship network of co-authors of Marc A. Pfeffer

This figure shows the co-authorship network connecting the top 25 collaborators of Marc A. Pfeffer. A scholar is included among the top collaborators of Marc A. Pfeffer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marc A. Pfeffer. Marc A. Pfeffer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ostrominski, John W., Mats Christian Højbjerg Lassen, Jawad H. Butt, et al.. (2025). Adiposity-Related Anthropometrics and Clinical Outcomes in Heart Failure With Mildly Reduced or Preserved Ejection Fraction. Journal of the American College of Cardiology. 86(20). 1760–1777. 2 indexed citations
2.
Neuen, Brendon L., Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Natriuretic Peptides, Kidney Function, and Clinical Outcomes in Heart Failure With Preserved Ejection Fraction. JACC Heart Failure. 13(1). 28–39. 8 indexed citations
3.
Chatur, Safia, Iris E. Beldhuis, Brian Claggett, et al.. (2024). Sacubitril/Valsartan in Patients With Heart Failure and Deterioration in eGFR to <30 mL/min/1.73 m2. JACC Heart Failure. 12(10). 1692–1703. 5 indexed citations
4.
Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Race in Heart Failure. JACC Heart Failure. 13(1). 58–71.
5.
Foà, Alberto, Muthiah Vaduganathan, Brian Claggett, et al.. (2024). Sacubitril/Valsartan-Related Hypotension in Patients With Heart Failure and Preserved or Mildly Reduced Ejection Fraction. Journal of the American College of Cardiology. 83(18). 1731–1739. 3 indexed citations
6.
Butt, Jawad H., John J.V. McMurray, Brian Claggett, et al.. (2024). Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant–Level Analysis of 6 Randomized Clinical Trials. Circulation. 150(23). 1858–1868. 3 indexed citations
7.
Shen, Li, Matthew M.Y. Lee, Pardeep S. Jhund, et al.. (2024). Revisiting Race and the Benefit of RAS Blockade in Heart Failure. JAMA. 331(24). 2094–2094. 2 indexed citations
8.
Lu, Henri, Brian Claggett, Milton Packer, et al.. (2024). Visit-to-Visit Changes in Heart Rate in Heart Failure: A Pooled Participant-Level Analysis of the PARADIGM-HF and PARAGON-HF Trials. European Journal of Heart Failure. 27(1). 60–68.
9.
Zannad, Faı̈ez, Filippo Crea, John F. Keaney, et al.. (2023). Rapid, accurate publication and dissemination of clinical trial results: benefits and challenges. European Heart Journal. 44(40). 4220–4229. 6 indexed citations
10.
Shah, Amil M., Brian Claggett, Narayana Prasad, et al.. (2022). Impact of Sacubitril/Valsartan Compared With Ramipril on Cardiac Structure and Function After Acute Myocardial Infarction: The PARADISE-MI Echocardiographic Substudy. Circulation. 146(14). 1067–1081. 32 indexed citations
11.
Merhi, Basma, Theresa I. Shireman, Myra A. Carpenter, et al.. (2017). Serum Phosphorus and Risk of Cardiovascular Disease, All-Cause Mortality, or Graft Failure in Kidney Transplant Recipients: An Ancillary Study of the FAVORIT Trial Cohort. American Journal of Kidney Diseases. 70(3). 377–385. 26 indexed citations
12.
Shah, Amil M., Sanjiv J. Shah, Inder S. Anand, et al.. (2013). Cardiac Structure and Function in Heart Failure With Preserved Ejection Fraction. Circulation Heart Failure. 7(1). 104–115. 327 indexed citations
13.
Sabatine, Marc S., David A. Morrow, James A. de Lemos, et al.. (2011). Evaluation of Multiple Biomarkers of Cardiovascular Stress for Risk Prediction and Guiding Medical Therapy in Patients With Stable Coronary Disease. Circulation. 125(2). 233–240. 108 indexed citations
14.
Shah, Amil M., Hajime Uno, Lars Køber, et al.. (2010). The Inter-Relationship of Diabetes and Left Ventricular Systolic Function on Outcome After High-Risk Myocardial Infarction. European Journal of Heart Failure. 12(11). 1229–1237. 39 indexed citations
15.
Hawkins, Nathaniel M., Duolao Wang, John J.V. McMurray, et al.. (2007). Prevalence and Prognostic Impact of Bundle Branch Block in Patients with Heart Failure: Evidence from the CHARM Programme. European Journal of Heart Failure. 9(5). 510–517. 45 indexed citations
16.
Solomon, Scott D., Joanna Dobson, Stuart Pocock, et al.. (2007). Influence of Nonfatal Hospitalization for Heart Failure on Subsequent Mortality in Patients With Chronic Heart Failure. Circulation. 116(13). 1482–1487. 457 indexed citations breakdown →
17.
Lewis, Eldrin F., Gervasio A. Lamas, Eileen O’Meara, et al.. (2006). Characterization of Health-Related Quality of Life in Heart Failure Patients with Preserved Versus Low Ejection Fraction in CHARM. European Journal of Heart Failure. 9(1). 83–91. 179 indexed citations
18.
Køber, Lars, Karl Swedberg, John J.V. McMurray, et al.. (2006). Previously Known and Newly Diagnosed Atrial Fibrillation: A Major Risk Indicator After a Myocardial Infarction Complicated by Heart Failure or Left Ventricular Dysfunction. European Journal of Heart Failure. 8(6). 591–598. 102 indexed citations
19.
Ridker, Paul M., Christopher P. Cannon, David A. Morrow, et al.. (2005). C-Reactive Protein Levels and Outcomes after Statin Therapy. New England Journal of Medicine. 352(1). 20–28. 1708 indexed citations breakdown →
20.
Pfeffer, Marc A., Janice M. Pfeffer, I. Mirsky, & Junichi Iwai. (1984). Cardiac hypertrophy and performance of Dahl hypertensive rats on graded salt diets. Hypertension. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by John J.V. McMurray Breakdown of academic impact, for papers by Daniel Levy Breakdown of academic impact, for papers by Gregg C. Fonarow Breakdown of academic impact, for papers by Deepak L. Bhatt Breakdown of academic impact, for papers by Christopher P. Cannon Breakdown of academic impact, for papers by Scott D. Solomon Breakdown of academic impact, for papers by Peter W.F. Wilson Breakdown of academic impact, for papers by Martin G. Larson Breakdown of academic impact, for papers by William B. Kannel Breakdown of academic impact, for papers by Eugene Braunwald
Rankless by CCL
2026